Comparison of surgical outcomes of emergent laparoscopic cholecystectomy for acute cholecystitis between attending surgeons and senior residents: A propensity-matched analysis

Asian J Endosc Surg. 2022 Oct;15(4):728-736. doi: 10.1111/ases.13069. Epub 2022 Apr 21.

Abstract

Introduction: Emergent laparoscopic cholecystectomy (LC) is routinely performed for acute cholecystitis (AC) at our institution. This study was conducted to investigate the feasibility and safety of emergent LC for AC performed by senior residents.

Materials and methods: Data from 362 patients with AC who underwent emergent LC between January 2012 and June 2020 were retrospectively reviewed. Of these patients, 328 were operated on by senior residents (SR), and 34 were operated on by the attending surgeon (AS). Clinical characteristics and surgical and postoperative outcomes were compared between the SR and AS groups. Propensity score matching was used to minimize selection bias. When the operator was an SR, the LC was assisted by the AS.

Results: Before matching, in the SR group, more patients had a history of abdominal surgery, and C-reactive protein and white blood cell counts were significantly higher. In the image findings, the minor axis of the gallbladder (GB) was longer, and the wall of the GB was thicker in the SR group. After propensity score matching, 28 pairs were identified. There were no significant differences in operative time (83 vs 88 minutes, P = .92), the amount of blood loss (25 vs 10 mL, P = .13), conversion to open surgery (3.6% vs 3.6%, P = 1), postoperative complications (7.2% vs 0%, P = .74), and postoperative hospital stay (4 vs 4 days, P = .87).

Conclusion: Emergent LC for AC performed by SR under supervision appears to be feasible and safe.

Keywords: acute cholecystitis; laparoscopic cholecystectomy; resident.

Publication types

  • Comparative Study

MeSH terms

  • C-Reactive Protein
  • Cholecystectomy, Laparoscopic* / methods
  • Cholecystitis, Acute* / surgery
  • Humans
  • Length of Stay
  • Retrospective Studies
  • Surgeons*
  • Treatment Outcome

Substances

  • C-Reactive Protein